Strides Pharma Falls 5.6% After Trump’s 100% Tariff Move on Branded Drug Imports

Mumbai, September 26, 2025 – The shares of Strides Pharma Science Ltd (NSE: STAR) plummeted by 5.62% during the early morning trade after US President Trump announced introducing a 100% import tariff on branded and patented pharmaceutical products. The share price consolidated slightly by 01:45 PM and reached ₹812.10 (down 3.25% from the previous close).

The decline stemmed from investor concerns that U.S.-focused Indian drugmakers could face margin pressures and revenue uncertainty.

Strides Pharma: Trade Snapshot

Strides Pharma’s stock traded at ₹812.10, down 3.25% from the previous close of ₹839.40. The day’s range was ₹786.80-₹829.50, with a traded volume of 1.05 lakh shares. The stock has experienced high volatility, with a 52-week high of ₹1,675 (October 2024) and a low of ₹513.05 (April 2025). Its current market capitalization stands at ₹7,310.68 crore, reflecting strong investor interest despite recent declines.

Sector Impact

The U.S. is the largest export market for Indian drugmakers, including Strides Pharma, with shipments worth billions of dollars annually. While the tariff announcement directly targets branded and patented drugs, analysts flagged the risk of spillover to complex generics and specialty products. Other major Indian pharmaceutical companies, such as Sun Pharma, Dr. Reddy’s, Lupin, and Aurobindo, also witnessed sharp declines, dragging the Nifty Pharma index lower in morning trade.

Key Triggers

The key triggers for the drastic fall can be attributed to yet another policy shock by the US President, which resulted in an overall selling panic in the pharmaceutical counters. Investors still require clarity on whether specialty generics fall under the tariff regime, which will be crucial in determining the sector’s outlook. The Nifty Pharma index also plummeted by more than 2% during the day, and has moved sideways since then.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations